300497SZSE
🚨 Material Event

2026 Plan for Issuance of A-Shares to Specific Targets

✨ AI Summary

Jiangxi Fushine Pharmaceutical Co., Ltd. plans to raise up to 700 million RMB through a private placement of A-shares to no more than 35 specific investors. The proceeds will fund the construction of a 20,000-ton FEC project, a high-quality triazole project, and working capital replenishment. The issuance price will be no less than 80% of the average trading price of the 20 trading days preceding the pricing benchmark date.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300497 Stock Abbreviation: Fushine Announcement No.: 2026-068

Jiangxi Fushine Pharmaceutical Co., Ltd.

2026 Plan for Issuance of A-Shares to Specific Targets

July 2026

Company Statement

  1. The Company and all members of the Board of Directors guarantee that the contents of this plan are true, accurate, and complete, and confirm that there are no false records, misleading statements, or major omissions, and assume individual and joint legal liability for its authenticity, accuracy, and completeness.

  2. This plan is prepared in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Administrative Measures for the Registration of Securities Issuance by Listed Companies.

  3. Upon completion of this issuance of shares to specific targets, the Company shall be solely responsible for changes in its operations and earnings; investors shall be solely responsible for investment risks arising from this issuance. Investors with any questions should consult their stock brokers, lawyers, professional accountants, or other professional advisors.

  4. This plan is the Board of Directors' explanation of this issuance of shares to specific targets, and any statement inconsistent with it is a false statement.

  5. The matters stated in this plan do not represent a substantive judgment, confirmation, or approval by the approval authorities regarding the matters related to this issuance. The effectiveness and completion of the matters related to this issuance are subject to the approval or consent for registration by the relevant approval authorities.

  6. Any content in this plan involving investment benefits or performance forecasts does not constitute a commitment by the Company to any investor or relevant person. Investors and relevant persons should understand the differences between plans, forecasts, or commitments and pay attention to investment risks.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.